Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Adults With Chronic Ischemic Stroke (EXA2611)
Proof-of-concept for Use of Transcutaneous Spinal Stimulation (TSS) With the ExaStim® Stimulation System in Chronic Stroke Population
The goal of this clinical trial is to learn about the safety, tolerability, and feasibility of ExaStim transcutaneous electrical stimulation combined with task-specific rehabilitation, and to characterize changes in arm function in adults with chronic unilateral ischemic stroke. The main questions it aims to answer are:
- Does 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation improve arm function?
- What are the safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke?
Participants will:
- Complete a 12-week intervention period combining ExaStim transcutaneous electrical stimulation with structured, task-specific rehabilitation
- Undergo clinical assessments and outcome testing baseline, week 4, week 8, week 12, and week 17 (follow-up)
- Monitor and report pain and quality of life via Visual Analog Scales (VAS) and questionnaires throughout the 17-week study duration
研究概览
详细说明
Primary exploratory clinical objective: To characterize change in upper extremity motor impairment following 12 weeks of ExaStim stimulation combined with structured, task-specific rehabilitation in individuals with chronic stroke.
Secondary objective: To characterize safety, tolerability, and feasibility of ExaStim use in individuals with chronic stroke. Exploratory objectives include describing immediate on/off-stimulation differences in dexterity and persistence of observed changes at Week 17; the design is not intended to establish causal effectiveness.
Additional exploratory outcomes:
- Change from baseline to Weeks 4, 8, and 17 in each of FMA-UE, ARAT, BBT, 9HPT, MAL, and SIS.
- Change from Week 12 to Week 17 in each of FMA-UE, ARAT, BBT, 9HPT, MAL, and SIS.
- Descriptive comparison of the group mean FMA-UE change from baseline to Week 12 with the exploratory 4.25-point reference.
- Change from baseline to Week 12 in Modified Ashworth Scale scores.
The FMA-UE screening range of 20-50 is supported by its use in chronic stroke neuromodulation studies, including VNS-REHAB (Dawson et al., 2021) and the TRICEPS protocol (Baig et al., 2025). This eligibility precedent does not establish a clinically meaningful change threshold for ExaStim. Page, Fulk, and Boyne (2012) reported clinically important differences of 4.25-7.25 points in chronic stroke with mild-to-moderate impairment, depending szon the therapist-rated anchor. Accordingly, 4.25 points will be used only as an exploratory reference when describing observed changes. Group mean change will summarize the overall magnitude of change, while individual changes and baseline scores will show participant variability. Neither a group mean nor an individual change of ≥4.25 points will define study success or a clinically meaningful responder in this proof-of-concept study.
Feasibility will be summarized using screening and enrollment counts, retention through Week 17, completed sessions out of 24 planned, sessions delivering at least 45 minutes of stimulated rehabilitation, actual stimulation minutes, interruptions, and reasons for missed visits or discontinuation. Twice-weekly paired BBT and 9HPT measurements will describe unstimulated trajectories and within-visit changes with stimulation. These summaries supplement the synopsis endpoints without changing their hierarchy. Feasibility measures will be reported descriptively with their denominators; no additional operational success thresholds are specified for this proof-of-concept study.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Emily Rosario, PhD
- 电话号码:3036 609-596-7733
- 邮箱:erosario@casacolina.org
研究联系人备份
- 姓名:Daniel Humphrey, PT, DPT, NCS
- 电话号码:3036 609-596-7733
- 邮箱:dhumphrey@casacolina.org
学习地点
-
-
California
-
Pomona、California、美国、91767
- Casa Colina Hospital and Centers for Healthcare
-
接触:
- Emily Rosario, PhD
- 电话号码:3036 609-596-7733
- 邮箱:erosario@casacolina.org
-
接触:
- Daniel Humphrey, PT, DPT, NCS
- 电话号码:3036 609-596-7733
- 邮箱:dhumphrey@casacolina.org
-
副研究员:
- Emily Rosario, PhD
-
首席研究员:
- Yannick Darmon, PT, PhD
-
副研究员:
- Daniel Humphrey, PT, DPT, NCS
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject must have a documented diagnosis of a singular unilateral ischemic stroke event confirmed by radiology report.
- Participant is in the chronic stage of neurological recovery, defined as at least 6 months after the unilateral ischemic stroke event.
- Subject is aged 18-75 years
- In the investigators or qualified clinician's judgment, the subject must possess sufficient global cognitive capacity to understand and follow study-related instructions, actively participate in task-specific rehabilitation, and provide informed consent. Cognitive capacity will be supported by the subject's ability to follow a three-step command and demonstrate orientation to person, place, time, and situation (4/4)
- Subject must have a Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score between 20 and 50 (inclusive) at screening.
- Subject must be able to commit to participating in a 17-week study, and be willing to comply with study instructions, agree to make all office and therapy appointments, and complete the entire course of the study
- Subject must be deemed medically stable for intensive physical rehabilitation and transcutaneous electrical stimulation, supported by formal written clearance from their primary care physician or managing neurologist.
- Subject must be able to understand the study, provide informed consent, and complete the applicable HIPAA authorization using IRB-approved procedures. Literacy alone is not an exclusion. IRB-approved accessible consent methods may be used when needed, while the investigator confirms the participant's own understanding, decision-making capacity, and ability to meet study communication requirements.
Exclusion Criteria:
- Active implanted medical device for electrical stimulation
- Index stroke is hemorrhagic or involves the brainstem, cerebellum, or thalamus, as confirmed by neuroimaging or medical records.
- Other internal metallic objects of unknown or foreign origin (unidentifiable surgical implants, shrapnel, bullet fragments, etc.)
- Botox injections to the upper limb(s) in prior 3 months
- Severe spasticity, MAS grade >3 (grade 4 only; grade 3 is not excluded by this criterion) in any of the following muscles: shoulder abductors, shoulder flexors, elbow flexors/extensors, wrist flexion, forearm supination or pronation, or finger flexors.
- Subject scores <20 or >50 points on the FMA-UE.
- BMI > 40.0 (morbid obesity)
- Acute medical conditions under active treatment that would contraindicate standard rehabilitation including open wounds, unhealed bone fractures, peripheral neuropathies or painful musculoskeletal dysfunction
- Subjects who are pregnant or planned pregnancy during the study. Participants of childbearing potential must agree to effective contraception for the duration of participation.
- Allergy to hydrogel, silicone, latex or other product materials
- Compromised skin in the area for electrode contact (back of neck and/or hip area)
- Uncontrolled cardiopulmonary disease or hypertension
- Presence of ongoing dysphagia or aspiration difficulties.
- Significant sensory impairments. Subjects who score below a 6 out of 12 on the sensory subscale (section H) of the Fugl Meyer Assessment will be excluded.
- Other symptoms that would prohibit use or cause discomfort from stimulation such as hypersensitivity.
- History of more than one stroke episode
- Severe contractures of upper extremity(s)
- Severe receptive and/or expressive aphasia limiting communication and understanding of device and interventions
- History of uncontrolled epilepsy or seizures
- Unmanaged depression, psychiatric disorders or ongoing substance abuse
- Participation in another clinical trial that may interfere with this study
学习计划
研究是如何设计的?
设计细节
- 主要用途:设备可行性
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ANEUVO ExaStim Stimulation System
|
Week 0 includes one baseline assessment session and two to three parameter optimization sessions. Participants will attend 2 rehabilitation sessions per week for 12 weeks, for a total of 24 sessions. Each session will provide ~60 minutes of rehabilitation, including at least 45 minutes of active stimulation delivered concurrently with therapeutic activity. The therapist will select activities according to participant goals, affected-arm capacity, movement quality, fatigue, pain, and cardiovascular tolerance. Each session will emphasize repeated practice, functional strength or functional practice. Missed sessions will be rescheduled within the 12-week period if appropriate. Separate assessment visits occur in Weeks 4, 8, 12, and 17 and may last approximately one to two hours with rest breaks. The final evaluation is scheduled for Week 17. All assessments will use the same participant-specific baseline date as the time reference, and actual visit dates and intervals will be recorded. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fugl-Meyer Assessment for Upper Extremity - Motor Score (FMA-UE)
大体时间:Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
The Fugl-Meyer Upper Extremity Assessment is a 66-point stroke-specific scale measuring sensorimotor recovery across reflexes, synergies, isolated movements, wrist stability, hand function, and coordination. Each item is scored from 0 to 2 based on performance completeness and compensation. Changes exceeding the minimal clinically important difference (typically 4 to 10 points) reflect meaningful gains in motor control and functional independence. |
Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Action Research Arm Test (ARAT)
大体时间:Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
The Action Research Arm Test (ARAT) is a 57-point, 19-item observational assessment measuring upper extremity functional capacity and dexterity across grasp, grip, pinch, and gross movement subscales. Each task is scored from 0 to 3 based on completion time, movement quality, and compensation patterns. A score change exceeding the minimal clinically important difference (typically 6 to 10 points) indicates meaningful improvement in real-world arm and hand function. |
Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
|
Box-and-Blocks Test (BBT)
大体时间:Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
|
The Box and Block Test measures unilateral gross manual dexterity by recording the number of one-inch wooden blocks a patient can transport over a partition from one compartment to another in 60 seconds. The scoring system simply counts the total number of successfully transferred blocks per hand, with multiple blocks carried simultaneously counting as a single point. An increase in score exceeding the minimal detectable change (typically around 6 or more blocks for stroke populations) indicates a true, statistically significant improvement in hand transport speed and unilateral functional capacity. |
Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
|
|
9-Hole Peg Test (9HPT)
大体时间:Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
|
The Nine-Hole Peg Test (9HPT) measures manual dexterity and finger-movement speed by recording the total seconds required for a patient to place and subsequently remove nine pegs into a board. Scoring is based on timing (seconds per trial), where lower times indicate better performance, or converted to "pegs per second" for rate-based analysis. A change in score exceeding the minimal detectable change (typically a reduction of several seconds or roughly 15 to 20% from baseline) indicates a statistically significant improvement in fine motor speed and coordination. |
Initial assessment at enrollment, at the start of each treatment session, and during re-assessment visits at weeks 4, 8, 12, and 17
|
|
Visual Analog Scale (VAS) for pain
大体时间:Initial assessment at enrollment, at the end of each treatment session, and during re-assessment visits at weeks 4, 8, and 12
|
The Visual Analog Scale (VAS) measures subjective symptom intensity, such as pain, using a continuous horizontal line anchored by "no symptom" at one end and "worst imaginable symptom" at the other. Patients mark their perceived level, and the score is quantified from 0 to 10, where higher numbers reflect greater symptom severity. A score change exceeding a 2 point change indicates a clinically meaningful improvement or worsening of the patient's symptom experience. |
Initial assessment at enrollment, at the end of each treatment session, and during re-assessment visits at weeks 4, 8, and 12
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Motor Activity Log (MAL)
大体时间:Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
The Motor Activity Log (MAL) is a structured, semi-structured clinical interview where stroke survivors rate their actual daily arm use in terms of Amount of Use (AOU) and How Well (HW) they perform 30 real-world functional tasks. Each item is scored on a 0-to-5 ordinal scale, ranging from 0 (not used at all) to 5 (used as well as before the stroke), with final scores derived from the average of all items. A change in score exceeding the minimal clinically important difference (typically around 1.0 to 1.1 points for either subscale) indicates a meaningful, real-world translation of laboratory motor gains into spontaneous, daily spontaneous arm use. |
Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
|
Stroke Impact Scale (SIS)
大体时间:Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
The Stroke Impact Scale (SIS) is a patient-reported outcome measure evaluating health-related quality of life across eight domains, including strength, hand function, ADLs, mobility, communication, emotion, memory, and participation. Each item is scored on a 1-to-5 ordinal scale, which is then transformed into a standardized 0-to-100 scale per domain, where higher scores reflect better recovery and fewer stroke-related limitations. A score change exceeding the minimal clinically important difference (typically ranging from about 3 to 17 points depending on the specific domain) indicates a statistically reliable and meaningful improvement in the patient's perceived recovery and daily well-being. |
Initial assessment at enrollment, re-assessment at weeks 4, 8, 12, and 17
|
|
Modified Ashworth Scale (MAS)
大体时间:Initial assessment at enrollment, re-assessment at week 12
|
Modified Ashworth Scale (MAS), it grades spasticity and muscle hypertonia on a 6-point ordinal scale from 0 (no increase in tone) to 4 (rigid limb in flexion or extension). A decrease in score indicates a reduction in passive resistance and muscle hypertonia, reflecting successful management of spasticity. |
Initial assessment at enrollment, re-assessment at week 12
|
合作者和调查者
调查人员
- 研究主任:Emily Rosario, PhD、Casa Colina Hospital and Centers for Healthcare
出版物和有用的链接
一般刊物
- Dawson J, Liu CY, Francisco GE, Cramer SC, Wolf SL, Dixit A, Alexander J, Ali R, Brown BL, Feng W, DeMark L, Hochberg LR, Kautz SA, Majid A, O'Dell MW, Pierce D, Prudente CN, Redgrave J, Turner DL, Engineer ND, Kimberley TJ. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet. 2021 Apr 24;397(10284):1545-1553. doi: 10.1016/S0140-6736(21)00475-X.
- Boonstra AM, Schiphorst Preuper HR, Balk GA, Stewart RE. Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain. Pain. 2014 Dec;155(12):2545-2550. doi: 10.1016/j.pain.2014.09.014. Epub 2014 Sep 17.
- Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995 May;61(2):277-284. doi: 10.1016/0304-3959(94)00178-H.
- Pinto Damo NL, Modesto KA, Neto IVS, Bottaro M, Babault N, Durigan JLQ. Effects of different electrical stimulation currents and phase durations on submaximal and maximum torque, efficiency, and discomfort: a randomized crossover trial. Braz J Phys Ther. 2021 Sep-Oct;25(5):593-600. doi: 10.1016/j.bjpt.2021.03.001. Epub 2021 Mar 26.
- Page SJ, Fulk GD, Boyne P. Clinically important differences for the upper-extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. Phys Ther. 2012 Jun;92(6):791-8. doi: 10.2522/ptj.20110009. Epub 2012 Jan 26.
- Powell MP, Verma N, Sorensen E, Carranza E, Boos A, Fields DP, Roy S, Ensel S, Barra B, Balzer J, Goldsmith J, Friedlander RM, Wittenberg GF, Fisher LE, Krakauer JW, Gerszten PC, Pirondini E, Weber DJ, Capogrosso M. Epidural stimulation of the cervical spinal cord for post-stroke upper-limb paresis. Nat Med. 2023 Mar;29(3):689-699. doi: 10.1038/s41591-022-02202-6. Epub 2023 Feb 20.
- Zamurd, N., & Obaid Baig, M. (2022). The correlation between Fugl Meyer Upper Extremity Scale and Action Research Arm Test as a measure of upper extremity rehabilitation in stroke patients. Stroke Research and Therapy, 6(6), 153. https://doi.org/10.36648/IPSRT.22.6.6.153
- Yao MC, Zhu SG, Yao CH. Gene amplification in Tetrahymena thermophila: formation of extrachromosomal palindromic genes coding for rRNA. Mol Cell Biol. 1985 Jun;5(6):1260-7. doi: 10.1128/mcb.5.6.1260-1267.1985.
- Uchiyama Y, Takebayashi T, Takahashi K, Amano S, Gosho M, Sakai M, Hashimoto K, Hachisuka K, Domen K. Estimating the minimal clinically important difference of upper extremity outcome measures in chronic stroke patients with moderate to severe impairment: a cross-sectional study. Top Stroke Rehabil. 2024 May;31(4):409-417. doi: 10.1080/10749357.2023.2259649. Epub 2023 Sep 24.
- Sakamoto D, Hamaguchi T, Nakayama Y, Abo M. Reliability and validity of a newly developed Action Research Arm Test for upper limb function assessment in patients with stroke: A comparison with the conventional version. PLoS One. 2026 Mar 24;21(3):e0334199. doi: 10.1371/journal.pone.0334199. eCollection 2026.
- Park JH, Chang Y, Park S, Song TJ. Burden of stroke in the United States of America, 1990-2021: a systematic analysis for the US burden of disease study 2021. Front Neurol. 2025 Aug 14;16:1609508. doi: 10.3389/fneur.2025.1609508. eCollection 2025.
- Oh J, Scheffler MS, Mahan EE, King ST, Martin CA, Dinh J, Steele AG, O'Malley MK, Sayenko DG. Combinatorial Effects of Transcutaneous Spinal Stimulation and Task-Specific Training to Enhance Hand Motor Output after Paralysis. Top Spinal Cord Inj Rehabil. 2023 Fall;29(Suppl):15-22. doi: 10.46292/sci23-00040S. Epub 2023 Nov 17.
- Moshonkina TR, Zharova EN, Ananev SS, Shandybina ND, Vershinina EA, Lyakhovetskii VA, Grishin AA, Shlyakhto EV, Gerasimenko YP. A New Technology for Recovery of Locomotion in Patients after a Stroke. Dokl Biochem Biophys. 2022 Dec;507(1):353-356. doi: 10.1134/S1607672922340087. Epub 2023 Feb 14.
- Moon Y, Zuleger T, Lamberti M, Bansal A, Mummidisetty CK, McKenzie KA, Yingling L, Madhavan S, Roth EJ, Lieber RL, Jayaraman A. Characterization of Motor-Evoked Responses Obtained with Transcutaneous Electrical Spinal Stimulation from the Lower-Limb Muscles after Stroke. Brain Sci. 2021 Feb 26;11(3):289. doi: 10.3390/brainsci11030289.
- Moon Y, Yang C, Veit NC, McKenzie KA, Kim J, Aalla S, Yingling L, Buchler K, Hunt J, Jenz S, Shin SY, Kishta A, Edgerton VR, Gerasimenko YP, Roth EJ, Lieber RL, Jayaraman A. Noninvasive spinal stimulation improves walking in chronic stroke survivors: a proof-of-concept case series. Biomed Eng Online. 2024 Apr 1;23(1):38. doi: 10.1186/s12938-024-01231-1.
- Hays SA, Adehunoluwa EA, Epperson JD, Malley KM, Porter AL, Gallaway HL, Swank C, Carrera AJ, Stevens C, Gillespie J, Arnold D, Kian S, Bynum ZS, Meyers EC, Bleker N, Naftalis RC, Foreman ML, Hamilton RG, Rennaker RL, Kilgard MP, Wigginton JG. Closed-Loop Vagus Nerve Stimulation Delivered With a Miniaturized System Produces Lasting Recovery in Individuals With Chronic Stroke. Stroke. 2026 Jan;57(1):38-49. doi: 10.1161/STROKEAHA.125.052937. Epub 2025 Oct 7.
- Flodin J, Mikkelsen C, Ackermann PW. Knee extensor force production and discomfort during neuromuscular electrical stimulation of quadriceps with and without gluteal muscle co-stimulation. Eur J Appl Physiol. 2022 Jun;122(6):1521-1530. doi: 10.1007/s00421-022-04949-9. Epub 2022 Apr 15.
- Daghsen L, Fleury L, Bouvier J, Zavanone C, Dupont S, Hummel FC, Rosso C. Evaluation of a shortened version of the Action Research Arm Test (ARAT) for upper extremity function after stroke: The Mini-ARAT. Clin Rehabil. 2022 Sep;36(9):1257-1266. doi: 10.1177/02692155221097322. Epub 2022 May 6.
- Chan NH, Ng SSM. Effects of transcutaneous electrical nerve stimulation on cognitive function and upper limb motor function in people with chronic stroke: a randomized controlled trial. Geroscience. 2026 Jun 13. doi: 10.1007/s11357-026-02351-3. Online ahead of print.
- Baig SS, Mooney C, McKendrick K, Duffy KEM, Ali AN, Redgrave JN, Herbert E, Waterhouse S, Su L, Drummond A, Dawson J, Dimairo M, Biggs K, Cooper C, Majid A. TRanscutaneous lImb reCovEry Post-Stroke (TRICEPS): study protocol for a randomised, controlled, multiarm, multistage adaptive design trial. BMJ Open. 2025 Mar 26;15(3):e092520. doi: 10.1136/bmjopen-2024-092520.
- Aderinto N, Abraham IC, Olatunji G, Kokori E, Hasan A, Uwishema O. Mapping the role of vagus nerve stimulation in post-stroke arm motor recovery. J Neuroeng Rehabil. 2025 Oct 15;22(1):215. doi: 10.1186/s12984-025-01759-w.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.